Shares of Pharmaceutical company Legend Biotech climbed 5.9% this morning. Here are some quick facts to get you started if you are interested in the stock:
-
Legend Biotech has logged a -22.0% 52 week change, compared to 22.2% for the S&P 500
-
LEGN has an average analyst rating of buy and is -29.14% away from its mean target price of $82.19 per share
-
Its trailing earnings per share (EPS) is $-2.58, which brings its trailing Price to Earnings (P/E) ratio to -22.6. The Health Care sector's average P/E ratio is 27.61
-
The company's forward earnings per share (EPS) is $-0.55 and its forward P/E ratio is -105.9
-
The company has a Price to Book (P/B) ratio of 9.12 in contrast to the Health Care sector's average P/B ratio is 3.69
-
The current ratio is currently 5.7, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $15.52 Million and the average free cash flow growth rate is 2.0%